Literature DB >> 25757878

Molecular mechanisms of drug resistance and its reversal in cancer.

Melis Kartal-Yandim1, Aysun Adan-Gokbulut1, Yusuf Baran1,2.   

Abstract

Chemotherapy is the main strategy for the treatment of cancer. However, the main problem limiting the success of chemotherapy is the development of multidrug resistance. The resistance can be intrinsic or acquired. The resistance phenotype is associated with the tumor cells that gain a cross-resistance to a large range of drugs that are structurally and functionally different. Multidrug resistance arises via many unrelated mechanisms, such as overexpression of energy-dependent efflux proteins, decrease in uptake of the agents, increase or alteration in drug targets, modification of cell cycle checkpoints, inactivation of the agents, compartmentalization of the agents, inhibition of apoptosis and aberrant bioactive sphingolipid metabolism. Exact elucidation of resistance mechanisms and molecular and biochemical approaches to overcome multidrug resistance have been a major goal in cancer research. This review comprises the mechanisms guiding multidrug resistance in cancer chemotherapy and also touches on approaches for reversing the resistance.

Entities:  

Keywords:  ABC transporters; apoptosis; bioactive sphingolipids; cancer; cell cycle alteration; multidrug resistance

Mesh:

Substances:

Year:  2015        PMID: 25757878     DOI: 10.3109/07388551.2015.1015957

Source DB:  PubMed          Journal:  Crit Rev Biotechnol        ISSN: 0738-8551            Impact factor:   8.429


  63 in total

1.  Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.

Authors:  Ning Ji; Yuqi Yang; Chao-Yun Cai; Zi-Ning Lei; Jing-Quan Wang; Pranav Gupta; Suneet Shukla; Suresh V Ambudkar; Dexin Kong; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2018-10-10       Impact factor: 8.679

Review 2.  Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors.

Authors:  Bernadette Xin Jie Tune; Maw Shin Sim; Chit Laa Poh; Rhanye Mac Guad; Choy Ker Woon; Iswar Hazarika; Anju Das; Subash C B Gopinath; Mariappan Rajan; Mahendran Sekar; Vetriselvan Subramaniyan; Neeraj Kumar Fuloria; Shivkanya Fuloria; Kalaivani Batumalaie; Yuan Seng Wu
Journal:  J Oncol       Date:  2022-05-09       Impact factor: 4.501

Review 3.  The significance of PAK4 in signaling and clinicopathology: A review.

Authors:  Xinbo Yu; Changwei Huang; Jiyuan Liu; Xinyu Shi; Xiaodong Li
Journal:  Open Life Sci       Date:  2022-06-20       Impact factor: 1.311

4.  Expression of genes and proteins of multidrug resistance in gastric cancer cells treated with resveratrol.

Authors:  Katarzyna Mieszala; Malgorzata Rudewicz; Agnieszka Gomulkiewicz; Katarzyna Ratajczak-Wielgomas; Jedrzej Grzegrzolka; Piotr Dziegiel; Sylwia Borska
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

5.  3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells.

Authors:  Zhe Liu; Yiming Sun; Haiyu Hong; Surong Zhao; Xue Zou; Renqiang Ma; Chenchen Jiang; Zhiwei Wang; Huabin Li; Hao Liu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

6.  [Cell Cycle Checkpoint Kinase and Drug Resistance of Lung Cancer].

Authors:  Zhiyin Ke; Ailing Liang; Yongjun Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-04-20

Review 7.  Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.

Authors:  Raúl Ortíz; Francisco Quiñonero; Beatriz García-Pinel; Marco Fuel; Cristina Mesas; Laura Cabeza; Consolación Melguizo; Jose Prados
Journal:  Cancers (Basel)       Date:  2021-04-24       Impact factor: 6.639

Review 8.  BAG family proteins contributes to autophagy-mediated multidrug resistance of tumor.

Authors:  Jufang Guo; Xuelian Du; Chaolin Li
Journal:  Clin Transl Oncol       Date:  2022-03-12       Impact factor: 3.340

9.  Identification of chemoresistance-associated microRNAs and hub genes in breast cancer using bioinformatics analysis.

Authors:  Ming Wu; Yujie Zhao; Nanxi Peng; Zuo Tao; Bo Chen
Journal:  Invest New Drugs       Date:  2021-01-04       Impact factor: 3.850

Review 10.  Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

Authors:  Nirmala Tilija Pun; Chul-Ho Jeong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.